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Prognosis in patients with suspected or known
ischemic heart disease and normal myocardial
perfusion: Long-term outcome and temporal
risk variations
Jane A. Simonsen, MD,a Oke Gerke, MSc, PhD,a,b Charlotte K. Rask, MD,a
Mohammad Tamadoni, MD,a Anders Thomassen, MD,a Søren Hess, MD,a
Allan Johansen, MD, DMSc,a Hans Mickley, MD, DMSc,c Lisette O. Jensen, MD,
PhD, DMSc,c Jesper Hallas, MD, DMSc,d Werner Vach, MSc, PhD,e and
Poul F. Høilund-Carlsen, MD, DMSca
Background. The prognostic value of a normal myocardial perfusion scintigraphy (MPS)
may be well described, but long-term follow-up data are sparse, and temporal variations in risk
are insufficiently elucidated.
Methods and Results. During long-term follow-up (mean 6.2 years) of 1,327 consecutive
Danish patients with normal MPS, the rate of all-cause death (ACD) was 1.9%/year (differing
by gender) and of cardiac death (CD)/myocardial infarction (MI) 0.8%/year (differing by
coronary artery disease, CAD). Female gender (HR: 0.60), age (HR: 1.07 per-year increment),
and known CAD without prior revascularization (HR: 2.17) were statistically significant factors
for ACD, whereas diabetes and previous MI per se were not. Known CAD with previous
revascularization carried a low risk of ACD when adjusted for gender and age (HR: 0.56). For
CD/MI, risk increased with age and threefold with known CAD, previous MI, and previous
percutaneous coronary intervention. Judged from smoothed hazard functions, mortality risk
increased further with time for men, elderly, and diabetics and markedly further with known
CAD without prior revascularization.
Conclusions. Following a normal MPS, rates of death and hard cardiac events were low.
Risk varied with age, gender, and disease history. Novel aspects of temporal risk variation
suggested a general warranty period of 5 years, but less in risk groups. (J Nucl Cardiol
2013;20:347–57.)
Key Words: Myocardial perfusion imaging: SPECT Æ diagnostic and prognostic application Æ
outcomes research Æ coronary artery disease
INTRODUCTION
A large body of literature exists documenting the
short-term prognostic value of myocardial perfusion
scintigraphy (MPS).1 A systematic review of English
language articles addressing the prognostic effectiveness
of single photon emission computed tomography
(SPECT) MPS in patients with suspected or known
coronary artery disease (CAD) was provided by Mowatt
et al.2 Typically, end points were cardiac death (CD) and
non-fatal myocardial infarction (MI), the so-called hard
cardiac events.1 It is well known that a normal stress
MPS implies a good clinical outcome with rates of hard
cardiac events and all-cause death (ACD) comparable to
those of the general population.3-5 Yet, these rates vary
from a low of 0.2% to a high of nearly 2%, reflecting
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differences in underlying clinical risk (age, co-morbid-
ity, etc.) and prior CAD.6-10 Especially, during the last
decade, there has been a growing recognition of the
importance of the underlying burden of atherosclerosis
as a primary determinant of prognosis.11 Furthermore,
ethnic and socioeconomic differences have been pin-
pointed.12,13 Recently, reports on long-term outcome
after (normal) MPS have also been emerging.14,15
Despite this wealth of information, gaps in our
knowledge base do still remain.11,16 These knowledge
gaps concern long-term outcome, in some cases reveal-
ing shifts in risk over time, thus refining our knowledge
on prognosis.11 Other related issues are post-test patient
management and patients’ differential needs for retest-
ing.16 We report on the long-term prognosis of patients
with normal MPS including differences with respect to
gender and co-morbidity and, in addition, new aspects of
temporal variations in risk.
METHODS
Study Design
We reviewed a consecutive series of MPS performed at
our institution during the years 2002–2007 (N = 4,850). We
included patients referred for suspected or known ischemic
heart disease and not included in research protocols in which
the result was kept blinded to the clinicians. In order to ensure
follow-up data availability, only persons from the regional
county (the former County of Funen, considered as represen-
tative for the entire country) and not referred from private
practicing cardiologists were included. In case a patient had
more than one examination during the 6-year period, only the
first was used. A total of 2,164 patients fulfilled the inclusion
criteria (Figure 1), and follow-up was successful in 99.7% of
these. Follow-up data were collected in January 2012 from the
national and regional registers. The number of deaths was
determined from the Danish Civil Personal Registration
System (records on all Danish citizens, living and deceased).17
Causes of death were established from the Danish Register of
Causes of Death (receiving all death certificates issued in
Denmark).18 CD was defined as death from ischemic heart
disease, congestive heart failure, or malignant arrhythmia
according to the death certificate. MI was noted if patients had
been assigned a diagnosis of ST elevation or non-ST elevation
MI according to the Danish National Patient Register (records
on all in- and outpatient diagnoses in Denmark).18 The number
of revascularization procedures was taken from the Western
Denmark Heart Registry (records on all coronary angiograph-
ies and revascularization procedures performed in Western
Denmark).19 Diabetics were identified as those taking pre-
scribed insulin or oral anti-diabetic drugs according to The
Odense Pharmacoepidemiological Database20 comprising all
prescriptions in the regional county. Mortality rates in age-
matched Danish citizens were obtained from Statistics Den-
mark (key authority on Danish statistics).18
MPS
MPS was performed as SPECT with technetium-99m
sestamibi (The Isotope Agency, Herlev, Denmark). The
protocol varied a little over the years: a standard 2-day rest-
stress; a 2-day stress-rest; or in recent years, a 1-day stress
procedure was carried out (in the latter case with addition of a
rest scan only in the case of an abnormal stress study). The
stress load consisted of a standard maximum exercise test or a
pharmacological stress test with adenosine, dipyridamol, or
dobutamine. For both rest and stress studies, imaging was
started 60 minutes after injection of sestamibi.
SPECT images were obtained on either of the two rotating
dual-headed detector gamma cameras fitted with low-energy,
high-resolution collimators. Scatter and attenuation correction
was not applied. Image acquisition variables were the follow-
ing: Marconi Axis camera (Marconi Medical Systems, Inc.,
Ohio, USA): matrix 64 9 64 or 128 9 128, pixel size 5.0 or
4.7 mm, and 68 or 120 projections (step-and-shoot technique)
with 20 seconds per projection over a 360 or 204 anatomical
orbit. Picker PRISM 2000 XP (Picker International, Inc., Ohio,
USA): matrix 64 9 64 or 128 9 128, pixel size 5.0 or
4.7 mm, and 60 projections (step-and-shoot technique) with
20 seconds per projection over a 180 or 360 elliptical orbit.
Datasets were reconstructed by iterative reconstruction
(OSEM) and post-filtered using a three-dimensional Butter-
worth filter (order, 2.5; cut-off, gated data, 0.21, ungated data,
0.37).
All scans were interpreted visually and semi-quantita-
tively using ungated short-axis, horizontal and vertical long-
axis myocardial tomograms. Initially, we used non-gated
acquisitions and bull’s eye displays, and a normal scan was
defined as a study with normal radionuclide distribution
throughout the myocardium. Later, gated studies were used
with left ventricular ejection fraction (LVEF) being available
in 960 of the patients. In 1,313 of the cases, a summed stress
score (SSS) was obtained using the AutoQuant software, and
a 20-segment model with 5-point grading: 0 = normal;
1 = equivocal; 2 = moderate; 3 = severe; or 4 = the com-
plete absence of visible radioactivity in a segment. A normal
scan was defined as one with an SSS of less than 4 and no
segments with a stress score of 2 or greater.21
Statistics
The primary end point was ACD, whereas composite end
points like (i) ACD or MI; (ii) CD or MI; and (iii) ACD, MI, or
coronary revascularization procedure were investigated as
exploratory secondary end points. For the latter, we only
included revascularization procedures performed [180 days
after MPS to cover new events, because revascularization
before then was considered driven by MPS results or based on
an indication established before MPS. For examination of the
rates of (cardiac) death and MI, patients were not censored in
case of revascularization before the event of interest. For
composite end points, only the time until the first event was
considered. Follow-up began on the date of the MPS and
continued until the date of the respective event, relocation, or
end of follow-up period (December 31, 2011, for CD;
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December 31, 2010 due to delay in registration of causes of
death), whichever happened first.
Results are presented as percentages for categorical
variables and descriptive statistics like mean (range) or
mean ± standard error of the mean (SEM) for continuous
variables. Incidence rates are reported. Differences in fre-
quency distribution were compared by Fisher’s exact test or the
chi-squared test. Intergroup differences in continuous variables
were tested by the unpaired Student’s t test. Multiple incidence
rate comparisons were done according to Boyd and Radson.22
Kaplan-Meier plots and log-rank tests were used in survival
analyses. Cox proportional hazards modeling was used to
describe the influence of covariates by calculation of both
unadjusted and adjusted hazard ratios. Adjustment was per-
formed for the most important confounders. Smoothed hazards
functions were used for estimation of mortality rates depending
on time. The significance level was set to 5%. Statistical
analyses were performed using STATA/MP 12 (StataCorp
LP, Texas, USA).
RESULTS
MPS was normal in 1,327 out of 2,157 eligible
patients (62%). Demographic data are shown in Table 1.
For those with a normal scan (43% male), mean age was
59.5 (15.5-88.5) years—80% were aged between 44 and
75 years. Diabetes mellitus (DM) was equally present in
men and women: 17% (95/574) vs 14% (107/753),
respectively, P = .25. Nineteen percent had known
CAD, but in women it was only 12% (89/753) compared
to 28% (159/574) in men, P \ .0001. Of diabetic
patients, 26% (53/202) had known CAD vs 17% (195/
1,125) of non-diabetics, P = .004.
Mean follow-up was 6.2 (0.02-9.96) years; total
follow-up was 8,231 person-years. Table 2 shows the
cumulative numbers of events during the follow-up
period. Of patients with normal MPS, 81% were event-
free survivors. Three percent experienced a non-fatal MI
while 12% died. Specific causes of death were ascer-
tained in 133 of the 157 deaths (85%). Of these, 10%
were classified as CDs and 90% as non-cardiac. Late
revascularization (percutaneous coronary interven-
tion (PCI) or coronary artery bypass graft surgery
(CABG) [ 180 days following MPS) was done in 7%.
For all types of events, the cumulative percentages were
higher for men than for women, for diabetic vs non-
diabetic patients, and for patients with known CAD
compared to those with suspected CAD.
For ACD, median time to event was 3.9 (0.02-9.4)
years. Incidence rates were, in terms of ACD: 1.9%/
year; ACD or MI: 2.4%/year; CD or MI: 0.8%/year; and
ACD, MI, or late coronary revascularization: 3.2%/year.
All-cause mortality rates differed according to gender
(men: 2.5%/year; women: 1.5%/year, P = .002), while
no differences were found in the subsets ?/-DM or
?/-CAD. Cardiac event rates differed only by CAD;
for CD or MI incidence rates were 1.8% vs 0.6% per
year (P = .0001) with vs without a history of CAD.
Incidence rates according to age are shown in Table 3.
The cardiac event rate exceeded 1% per year only in
the group of patients C85 years old. The all-cause
mortality rate was 1.5%/year for patients \75 years
old and 6.0%/year for patients C75 years old,
P \ .00001.
Kaplan-Meier survival estimates were calculated for
all end points. Those for ACD and the composite end
point of death, MI, or late revascularization are depicted
in Figure 2. With respect to gender, the differences were
apparent for all end points (Figure 2A). The group of
diabetics was small, and the curves did not differ
Figure 1. Outline of patient selection MPS, Myocardial perfusion scintigraphy; Susp., suspected;
CAD, coronary artery disease; Tx, transplantation.
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significantly with regard to death or death/MI, but when
late revascularization was also taken into account,
diabetics had significantly more events than non-diabetic
patients (Figure 2B). For patients with known CAD, no
differences were observed in mortality rates, but regard-
ing the composite end points, the difference was distinct
and more so when late revascularization was included
(Figure 2C).
Results of a Cox proportional hazards analysis are
shown in Table 4. In univariate models, female gender
(HR: 0.60), age (HR: 1.07 per one year’s increment), and
known CAD without previous PCI/CABG (HR: 2.17)
were statistically significant factors for the primary end
point, whereas the effects of DM, known CAD with
previous revascularization, and previous MI were non-
significant. Women with normal MPS were a little older
than men with normal scans (60.2 ± 0.4 vs 58.6 ±
0.5 years, P = .02), and after adjustment for age, the
gender difference in mortality rates was even more
marked. The effect of gender persisted when adjusted for
DM or CAD. The effect of known CAD with no previous
revascularization became insignificant when adjusted for
gender and age, whereas known CAD with previous
revascularization carried a lower risk for ACD when
adjusted for gender and age. For CD or MI, risk increased
with age and threefold with known CAD, previous MI,
and previous PCI.
Smoothed hazard functions (the estimated risk of ACD
at every time point) are outlined in Figure 3. For the whole
population with normal MPS, there was a very low risk in
the beginning, increasing slowly during the first 3 years to
reach a plateau, not surpassing 2% in the first 5 years.
Except from the outset, risk—albeit low—was higher than
in the age-matched general population (Figure 3A). The
risk of women increased more smoothly during the whole
period and surpassed 2% after 7 years (Figure 3B). For
Table 1. Demographic data
All (N 5 2,157)
Normal MPS
(N 5 1,327)
Abnormal MPS
(N 5 830)
Males 1,152 (53%) 574 (43%) 578 (70%)
Age ± SEM (years) 60.9 ± 0.2 59.5 ± 0.3 63.1 ± 0.4
Known CAD 720 (33%) 248 (19%) 472 (57%)
Previous MI 394 (18%) 87 (7%) 307 (37%)
Previous PCI 400 (19%) 149 (11%) 251 (30%)
Previous CABG 219 (10%) 59 (5%) 160 (19%)
Medically treated DM 407 (19%) 202 (15%) 205 (25%)
Exercise stress test 453 (21%) 369 (28%) 84 (10%)
Adenosine 1,565 (73%) 865 (65%) 700 (84%)
Dobutamine 126 (6%) 86 (7%) 40 (5%)
Dipyridamol 13 (0.6%) 7 (0.5%) 6 (0.7%)
Use of acetyl salicylic acid 1,468 (68%) 797 (60%) 671 (81%)
Use of b/a blocker 930 (43%) 462 (35%) 468 (56%)
Use of calcium channel blocker 558 (26%) 325 (24%) 233 (28%)
Use of nitrates 497 (23%) 279 (21%) 218 (26%)
Use of lipid-lowering agents 988 (46%) 481 (36%) 507 (61%)
Hypertension (N = 1,046) 537 (51%) 218 (53%) 319 (50%)
Smoking (N = 925)
Current 260 (28%) 98 (26%) 162 (29%)
Never 282 (30%) 136 (37%) 146 (26%)
Ceased 383 (41%) 137 (37%) 246 (44%)
Family history of CAD
(N = 1,017)
475 (47%) 203 (51%) 272 (44%)
SSS ± SEM 5.6 ± 0.2 (N = 1,313) 2.0 ± 0.1 (N = 814) 11.4 ± 0.4 (N = 499)
Stress LVEF ± SEM (%) 57.4 ± 0.4 (N = 895) 62.6 ± 0.4 (N = 536) 49.6 ± 0.7 (N = 359)
Rest LVEF ± SEM (%) 58.2 ± 0.5 (N = 906) 63.9 ± 0.4 (N = 494) 51.4 ± 0.7 (N = 412)
MPS, myocardial perfusion scintigraphy; SEM, standard error of the mean; CAD, coronary artery disease;MI, myocardial infarction;
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; DM, diabetes mellitus; SSS, summed stress
score; LVEF, left ventricular ejection fraction.
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patients aged C75 years the increase was steep with risk
being 2% in the beginning but [10% in 7 years (Fig-
ure 3C). Diabetics and non-diabetics shared risk for the
first 3 years, whereupon the risk of diabetics rose steadily
over 4 years (Figure 3D). For patients with merely the
suspicion of CAD the risk was below 2% for the first
4 years. The risk of patients with known CAD and a history
of revascularization (N = 194, 15% of all) had a small
initial top but stabilized at a lower level after five years. The
group with known CAD and no previous revascularization
(N = 54, 4% of the patients) had the highest and fastest
growing risk, reaching 6% in 4 years. All deaths in this
group occurred within 5 years from MPS (Figure 3E).
Including MI into the definition (i.e., known CAD with
prior revascularization or MI (N = 216, 16% of all) vs
known CAD with no prior revascularization or MI
(N = 32, 2% of all)) gave the same picture; only the peak
risk with no history of revascularization/MI was even
higher (7%) and maximum time-to-event shortened to
4.2 years (Figure 3F).
DISCUSSION
In this study of patients with definite or suspected
CAD, 62% of MPS were normal, indicating no significant
coronary artery lesion causing ischemia, quite in line with
earlier observations.23,24 Patients with normal MPS gener-
ally had a favorable long-term prognosis with respect to
ACD (1.9%/year) and hard cardiac events (0.8%/year),
comparable with previous findings from Europe and the
US. However, the risk was higher than that of the general
population, which is consistent with the findings of
Schinkel et al.15 Events occurred relatively late, as previ-
ously reported from our institution in a study of similar
patients, in which, however, a smaller sample size pre-
vented proper estimation of the relative influence of the
underlying risk factors.25 The present study had the power
to demonstrate that risk varied according to gender, age,
and CAD and that in some subgroups risk changed
dramatically over time.
Gender and Age
Men had a lower frequency of normal scans, consistent
with previous findings.26 Men with normal MPS had
significantly more events than women. Indeed, their risk
equated that of diabetic patients, whereas women had a risk
similar to non-diabetic patients. A low risk of death and
cardiac events in women with normal MPS has previously
been reported,6,12 even in women with a high pre-test
likelihood of disease.27 However, others described that in
the presence of DM or CAD women had prognoses equally
severe to that of men.28-30 In a report by Hachamovitch
et al, event rates were greater in diabetic vs non-diabetic
women, although no such difference was present in men,
and with known CAD, female diabetics had event rates
similar to male diabetics and non-diabetics, whereas non-
diabetic women had lower event rates.8 We found no
interaction between gender and DM or CAD.
As expected, in Cox modeling of hazards age was a
predictor of both ACD and hard cardiac events, and
event rates in the elderly were well beyond 2% per year.
All-cause mortality rates and CD rates for patients aged
75-84 years and aged C85 years were in line with those
reported by Hachamovitch et al.31
Diabetes Mellitus
In contrast to a recent update stating markedly higher
annual death rates in diabetic patients even with normal
MPS,1 DM itself was not a significant predictor of ACD or
CD/MI in our sample. Giri et al30 observed a lower
unadjusted cardiac survival rate in diabetics than non-
diabetics, which, however, became comparable once
adjusted for the pre-test clinical risk and stress MPS
results. Likewise, others concluded that the increased risk
Table 3. Mortality rates according to age
Age
(years)
Number of
subjects
Mortality rate
(% per year)
Time at risk
(years) for ACD
Cardiac mortality
rate (% per year)
Time at risk
(years) for CD
15–24 8 2.1 47 0 40
25–34 23 0.6 170 0.7 148
35–44 116 0.4 758 0.2 652
45–54 294 0.7 1,923 0 1,646
55–64 459 1.7 2,866 0 2,464
65–74 288 2.6 1,728 0.2 1,482
75–84 131 5.8 701 1.0 611
85–94 8 7.9 38 6.0 33
ACD, all-cause death; CD, cardiac death.
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of diabetic patients was the result of a high prevalence of
CAD and other risk factors.10,27
Coronary Artery Disease
The lower prevalence of known CAD in women
referred for stress MPS was in the same order of
magnitude as reported by Zafrir et al28 while in
other studies, there was only a small gender differ-
ence.8 Cardiac event rates differed by ?/-CAD to a
similar extent as shown by others.8,9 As expected
and also in line with previous findings,9 CAD was a
stronger predictor of hard cardiac events than of
ACD. Thus, even with a normal MPS, risk appears
Figure 2. Kaplan-Meier survival estimates of (left column) death and (right column) death, MI, or
late revascularization for (A) men (dashed red line) vs women (solid blue line), (B) diabetics
(dashed red line) vs non-diabetics (solid blue line), and (C) known CAD (dashed red line) vs
suspected CAD (solid blue line). Abscissa analysis time (years), ordinate survival probability,
below curves number of patients at risk.
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to be more differentiated than recognized in previous
times.32
Time Warranty
Compared with the continuously low mortality risk in
the general population, the risk of patients with normal
MPS was lower immediately after scintigraphy, increasing
for the first 3 years but then stabilizing at a 2% level
maintained within 5 years. This may suggest a general
warranty period following a normal MPS of 5 years. The
risk of diabetics stood out from that of non-diabetics after
3 years (Figure 3D) favoring the argument to retest dia-
betic patients with normal studies earlier than non-diabetic
ones in case of clinical symptom worsening.30 The risk of
the elderly diverged from that of the younger patients early
on and to an increasing extent (Figure 3C). Similarly, a
model for prediction of time to hard events in patients with
no previous CAD and normal MPS proposed by Hacha-
movitch et al8 included a nonlinear term for age.
Table 4. Cox proportional hazards regression models
ACD CD or MI
Hazard ratio CI P value Hazard ratio CI P value
Gender (women vs men)
Univariate analysis 0.60 [0.44, 0.82] .001 0.67 [0.39, 1.15] .15
Adjusted for age 0.51 [0.37, 0.71] \.0001 0.60 [0.35, 1.03] .07
Adjusted for DM 0.60 [0.44, 0.83] .002 0.67 [0.39, 1.16] .15
Adjusted for known CAD 0.61 [0.44, 0.84] .002 0.82 [0.47, 1.42] .48
Age (one year’s increase)
Univariate analysis 1.07 [1.06, 1.09] \.0001 1.06 [1.03, 1.09] \.0001
Adjusted for gender 1.08 [1.06, 1.09] \.0001 1.06 [1.03, 1.09] \.0001
DM
Univariate analysis 1.32 [0.89, 1.97] .17 1.30 [0.65, 2.59] .46
Adjusted for gender and age 1.13 [0.76, 1.69] .54 1.14 [0.57, 2.28] .71
Adjusted for known CAD 1.30 [0.87, 1.94] .20 1.14 [0.57, 2.27] .72
Known CAD
Univariate analysis 1.21 [0.82, 1.78] .33 2.98 [1.72, 5.17] \.0001
Adjusted for gender and age 0.75 [0.50, 1.11] .15 2.20 [1.23, 3.92] .01
Adjusted for DM 1.18 [0.80, 1.74] .40 2.95 [1.70, 5.14] \.0001
Known CAD with no previous PCI/CABG vs no CAD known
Univariate analysis 2.17 [1.20, 3.92] .01 3.43 [1.34, 8.82] .01
Adjusted for gender and age 1.68 [0.92, 3.06] .09 2.87 [1.11, 7.44] .03
Adjusted for DM 2.13 [1.18, 3.86] .01 3.41 [1.32, 8.76] .01
Known CAD with previous PCI/CABG vs no CAD known
Univariate analysis 0.97 [0.61, 1.53] .88 2.87 [1.57, 5.22] .001
Adjusted for gender and age 0.56 [0.35, 0.90] .02 2.04 [1.09, 3.82] .03
Adjusted for DM 0.94 [0.59, 1.50] .80 2.83 [1.55, 5.18] .001
Previous MI
Univariate analysis 1.05 [0.55, 1.99] .89 3.66 [1.83, 7.29] \.0001
Adjusted for gender and age 0.81 [0.43, 1.55] .53 3.06 [1.53, 6.13] .002
Previous PCI
Univariate analysis 0.81 [0,47, 1.41] .46 2.73 [1.46, 5.10] .002
Adjusted for gender and age 0.52 [0.30, 0.91] .02 2.02 [1.06, 3.84] .03
Previous CABG
Univariate analysis 1.05 [0.52, 2.14] .89 2.06 [0.82, 5.18] .13
Adjusted for gender and age 0.56 [0.27, 1.16] .12 1.27 [0.49, 3.27] .62
Adjusted hazard ratios refer to models with two or three covariates: The covariate of interest, for which the effect is reported, and
the covariate(s) adjusted for.
MI, myocardial infarction; CI, 95% confidence interval; DM, diabetes mellitus; CAD, coronary artery disease; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft surgery; ACD, all-cause death; CD, cardiac death.
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For patients with known CAD, risk changed over
time, as was also described in the past.8,9 Yet, further
stratification showed that after the first few years risk
increased rapidly in a small group of patients with CAD
without previous revascularization (Figure 3E, F). One
possible explanation could be that revascularization,
although indicated, was abandoned in patients with a
higher co-morbidity. In any case, such method of
stratification is new since traditionally only two catego-
ries (?/-CAD) were considered. Hachamovitch et al
found differentiated survival for patients with no prior
CAD, prior revascularization, but no prior MI, and prior
MI in a recent article on the impact of ischemia and scar
on the therapeutic benefit from myocardial revascular-
ization (45% of MPS abnormal).33 To our knowledge,
such stratification was never made in patients with
normal MPS, and our finding of a risk up to 6-7% in
spite of a normal MPS for patients with known CAD
with no prior revascularization is notable, since these
numbers are somewhat higher than those usually reck-
oned. Therefore, our data indicate that follow-up should
be closer in patients with existing CAD or higher risk
equivalents like diabetes or old age—quite in agreement
with prior proposals.8-10,15,31,34,35
A scientific basis for timing of repeat testing has
been sought after. In the cases of alterations in the
patient’s symptoms or functional capabilities, re-testing
may be considered when risk begins to accelerate.11
Compared with the study of Hachamovitch et al8 dis-
cussing the existence of a warranty period from their
2-year follow-up of [7,000 patients with normal MPS,
our follow-up period was appreciably longer ([6 years),
and the most dramatic increases in risk did not occur
until after the first two years. In contrast to the reporting
of averaged annualized event rates or event rates in
circumscribed time intervals after the index study, we
used smoothed hazard functions. The strength of these
curves is the reflection of the risk at every time point,
yielding an opportunity to read tendencies, time points
of transboundary risk, and differences between sub-
groups. Carryer et al tested the timing and type of
follow-up studies compared with the warranty periods
calculated from Hachamovitch’s data.36 They found that
in patients without prior CAD, follow-up MPS was
generally performed well before the end of the warranty
period, whereas in patients with known CAD (for whom
the warranty period was much shorter), they were on
average performed after the expiry of the warranty
Figure 3. Smoothed hazard functions for ACD. (A) Solid blue line the whole population with
normal MPS. Dashed red line with dots the age-matched general population. (B) Gender. Solid blue
line women. Dashed red line men. (C) Age. Solid blue line patients \ 75 years. Dashed red line
Patients C 75 years. (D) DM. Solid blue line non-diabetics. Dashed red line diabetics. (E) CAD.
Solid blue line no known CAD. Dashed red line: known CAD, history of revascularization. Dash-
dotted green line known CAD, no history of revascularization. (F) CAD. Solid blue line no known
CAD. Dashed red line known CAD, history of revascularization or MI. Dash-dotted green line
known CAD, no history of revascularization or MI. Abscissa analysis time (years), ordinate annual
mortality rate.
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period. However, as stated in a related editorial, rather
than a measure of the time to a certain risk of hard
events, what is really needed is a measure of the time to
develop an abnormal MPS that would allow for an
intervention of prognostic benefit to the patient.37
Advantages and Limitations
Large-scale studies on long-term prognosis with
normal MPS are still sparse, and such Scandinavian data
do not exist.25,38 In the European context, reported follow-
up periods were 10, 11, and 15 years, respectively, in only
47, 294, and 233 patients with normal MPS,14,15,35 How-
ever, in small, low-risk populations a consequently low
overall event rate precludes differentiation of risk.39 The
strengths of the present study are the large population, the
completeness of follow-up, and a follow-up period suffi-
ciently long to allow for the prognostic importance of
underlying risk factors to become unmasked with the
opportunity of bringing new aspects to changes in risk over
time. In Denmark, owing to national and regional record-
ings of all diagnoses, prescriptions, and deaths, the
possibilities to identify and follow large patient subsets
for a long time are very favorable.
Methodological problems in the prognostic literature
pointed out by Dr Hachamovitch16 were addressed since
we did not censor patients in case of early revascular-
ization leading to removal of high-risk patients, and we
used ACD as the primary end point. We did this because
of the delay in registration of causes of death in addition
to the well-described difficulties encountered in deter-
mining the actual cause of death, not to mention the
association of CAD with other co-morbid conditions
known to be factors independently predictive of
death.9,40 However, since in our low-risk population
only 10% of deaths were cardiac, predictors of CD could
be masked, and we, therefore, also modeled the risk of
hard cardiac events.
Inclusion of late revascularization in a composite
end point added to the understanding of the prognosis,
since late revascularization could be a proxy for a
change in clinical status (e.g., new anginal symptoms)
that might signify a shortening of the post-normal MPS
low risk warranty.
As measurements of LVEF were not available in all
patients because of early technical limitations we did not
risk stratify according to this variable. Patients were not
formally tested for the presence of DM, and hence the
‘‘non-diabetic’’ group may have contained undiagnosed
diabetics and patients with non-pharmacologically treated
DM that may have diluted some of our results. With regard
to previous findings of a higher mortality rate among the
pharmacologically challenged patients,7,8,41,42 we could
not deduce information from the type of stress performed,
since in recent times, we for practical reasons chose to use
pharmacological stress independently of the estimated
work capacity of the patient.
CONCLUSIONS
During a period of up to 10 (mean 6.2) years
following normal MPS, rates of ACD (1.9%/year) and
hard cardiac events (0.8%/year) were low, but higher
than in the general population. Event rates varied with
gender, age, and known CAD. Of particular interest,
patients with known CAD, but no prior revasculariza-
tion, constituted a subset with the highest and fastest
growing mortality risk, reaching 6% in 4 years. Another
novel finding was that events occurred relatively late,
suggesting a general warranty period of 5 years, but
somewhat shorter in risk groups.
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